THE CURIOUS CASE OF LOMITAPIDE
Lomitapide is a new Microsomal transfer protein inhibitor. It has been approved as an orphan drug for treating homozygous familial hypercholetelemia. The drug went through various see-saw phases in its brief life. Understanding the life history of Lomitapide gives a unique opportunity to analyze diverse case scenarios during clinical trials and their rectification by using scientific methodology.Â
2. FDA approves new orphan drug for rare cholesterol disorder. FDA NEWS RELEASE (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm, assessed on 1st May 2014)
3. Paracelsus. Toxipedia (http://www.toxipedia.org/display/toxipedia/Paracelsus, Accessed on 1st September 2014)
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.